Candida overgrowth and invasion constitute a serious threat with a high mortality in BMT recipients. Currently available topical antifungal prophylaxis is largely ineffective, and as resistance to existing, absorbable drugs for systemic use is rapidly developing, new forms of therapy are needed. We investigated the effect of oral treatment of BMT recipients with a bovine immunoglobulin product derived from animals immunized against several Candida species. The natural Candida colonization was first followed in 19 patients to establish the colonization pattern. Half of the patients were found to be colonized prior to transplantation and altogether 72% were colonized at some point during follow-up. Those with a high pre-transplant concentration of Candida in saliva (Ͼ100 CFU/ml) remained colonized throughout the BMT treatment period. The therapeutic effect was monitored in two other patient groups. The first group consisted of nine patients, where, due to a low number of primary colonized patients, response in colonized patients was suggestive of a therapeutic effect. In the second group, 10 patients with a high level of colonization (Ͼ100 CFU/ml) were given 10 g daily of the product in three divided doses. The results suggest a treatment-related reduction in Candida colonization in a majority (7/10) of patients and one patient became completely negative. As no adverse effects were noted, our findings encourage additional studies in immunocompromised, transplant patients.
of fatal yeast infections. 3, 4 However, invasive candidiasis is a serious clinical problem with a mortality ranging between 58-70%, and in systemic aspergillosis, the mortality rate is even higher. 5, 6 The majority of infections are caused by different Candida species and occur during the neutropenic phase early after transplantation when gastrointestinal overgrowth of Candida is likely to contribute to the development of invasive infections. Candida is endogenous and colonization has previously been documented in up to 76% of BMT subjects at our department. 7 Candida may enter the blood stream from a colonized mucosal surface, causing an infection with different organ involvement and candidemia which, in the BMT recipient, is often associated with a disseminated infection. Thus, antifungal prophylaxis is currently mandatory in BMT patients. However, the effectiveness of existing topical prophylactic regimens in BMT recipients is at present controversial and oral prophylaxis with polyene antibiotics such as nystatin and amphotericin B has been largely unsuccessful. [8] [9] [10] However, systemic prophylaxis with fluconazole, has been shown in previous studies to prevent many types of Candida infections. 11 Administration of human immunoglobulin to immunocompromised patients offers an alternative or adjunct therapy in the treatment and prevention of infections (for review see Ref. 12) . Treatment can be given either systemically or topically, ie as nose drops or as a drinking solution. The latter has also been used successfully as prophylaxis against bacterial infections in BMT recipients. 13, 14 Unfortunately, the titer against most pathogens in the available human gammaglobulin preparations is low and, as the cost for these products is high, alternative, more economical sources of antibodies must be sought.
Oral administration of bovine antibodies, derived from the colostrum of immunized cows, is currently being used increasingly for passive immunity in patients with a variety of oral and gastro-intestinal infections. 12, 15 The product is safe and has previously been suggested as a cost-effective prophylaxis against Candida overgrowth in patients with HIV. 16 The objectives of this study were to define suitable patient populations most likely to benefit from antibody therapy and to determine efficacy and safety of fungal prophylaxis by reducing fungal colonization using oral administration of bovine antibodies against Candida in allogeneic BMT recipients.
Patients studied in detail for natural course of candida colonization in saliva (n = 19)
Patients excluded from Ig treatment group 2 due to low or undetectable CFU/ml of Candida or drop out for other specified reasons (n = 21) Treatment group 1. Consecutive patients with or without Candida colonization (n = 9) Treatment group 2. Patients with >100 CFU/ml of Candida in saliva (n = 10) Non-Ig-treated patients (n = 40)
Ig-treated patients (n = 19)
Total number of BMT patients enrolled (n = 59) Figure 1 Flow chart of the patients enrolled in the different study groups.
Patients and methods

Patients
Fifty-nine consecutive allogeneic BMT patients were enrolled in the study between January 1996 and June 1997. The patients were divided into three main groups ( Figure  1 ), one which consisted of 19 control patients who did not receive antibody treatment and in whom only fungal colonization was studied and two groups of antibody-treated patients. In the initial therapeutic study (n ϭ 9), patients who were either free of oral yeast or colonized before BMT were all given the antibody preparation. In the second treatment group, 11 of the 31 patients screened and who showed a high concentration of yeast in the initial mouth wash sample (Ͼ100 CFU/ml) were treated. One patient in this group was later given systemic antifungal therapy and was excluded from the study.
There were 31 male and 28 female patients. Their median age was 37 with a range of 6 to 57 years. Underlying diseases were severe aplastic anemia in two patients, acute myeloid leukemia in 17, acute lymphocytic leukemia in 11, lymphoma in two, chronic myeloid leukemia in 21, myelofibrosis in two, chronic lymphocytic leukemia in two and myelodysplastic syndrome and myeloma in one patient each. The leukemias were classified as low-risk (first remission or chronic phase) in 40 patients and as high-risk (уsecond remission or relapse) leukemias in 19 cases. In 24 cases, transplantation was performed from HLA-identical siblings, in 33 cases with matched unrelated donors and in one case each, a one HLA-antigen mismatched sibling or unrelated donor. Conditioning prior to BMT consisted of total body irradiation and cyclophosphamide in 56 patients and busulfan and cyclophosphamide in the remaining three. 17 Prophylaxis against graft-versus-host disease included methotrexate and cyclosporine in 52 patients, cyclosporine combined with prednisolone in five and in two patients, cyclosporine monotherapy or T cell-depleted bone marrow (see Ref. 18 ).
Treatment regimen
All patients treated were scheduled to receive 10 g of bovine anti-Candida antibody product containing 4.2 g of IgG, divided in three doses daily from day 4 before transplant to day 28 post-transplant. The product was administered orally as a swish and swallow formula.
The study was approved by the local ethical committee of the Karolinska Institute at Huddinge Hospital and approval was also granted from the Swedish Medical Products Agency. Each patient also gave informed consent to participating in the study.
The bovine immunoglobulin product was concentrated from colostrum obtained during the first six postpartum milkings of cows immunized with a preparation of killed Candida albicans organisms (grown at 35°C to ensure expression of surface adhesins) and mannan, purified as described previously. 19 Colostrum was frozen immediately after collection and stored frozen until processing. Thawed colostrum was pooled and skimmed. The skim was acidified to precipitate the casein, which was removed by centrifugation. The supernatant was concentrated, heat-treated and spray-dried to produce the bulk powder product. Immunoglobulins constituted approximately 50% of the total protein content in the final product with an estimated ELISA titer of 6400 (unimmunized animals having a titer of Ͻ100).
In the first group treated, the antibody powder given was mixed with water or milk. Due to the altered taste and smell sensitivities of this patient population, the mixture was not well accepted although compliance remained reasonably high. Subsequently, the antibody powder was mixed with a chocolate drink, resulting in an improved acceptance of the product and no dropouts due to the drug itself were noted although mucositis, as expected, still caused problems with compliance.
Unless otherwise stated, all patients also received topical nystatin suspension (100 000 units/ml, 2 ml four times daily) throughout the study as antifungal prophylaxis as this regimen is part of standard care management. As mentioned above, one patient who received systemic antifungal therapy during the course of this study (liposomal amphotericin B), was excluded from evaluation.
Sampling schedule
Yeast isolation and quantitative colony counts: Mouth wash samples were scheduled to be taken on days Ϫ4, 3, 7, 10, 14, 17, 21, 28 and 31 after BMT (referred to as sample Nos 1, 2 etc). The oral cavity was washed with 10 ml of distilled water and the specimen was collected in a sterile container. The mouth wash specimen was collected before the patient had breakfast or had brushed his/her teeth. Part of the mouth wash (0.1 ml) was inoculated in duplicate on Sabouraud agar plates with antibiotics (Sab). The remaining mouth wash specimen was passed through a filter. Thereafter, the filter was applied to a Sab agar plate. All plates were incubated for 48 h at 37°C, after which colonies on the plates were counted and the CFU/ml of mouth wash was calculated.
The germ tube test was performed in all yeast isolates and all positive samples were identified as Candida albicans. Germ tube negative isolates were identified by the commercial API system (ID32C, Bio Merieux, France).
Measurement of systemic uptake of bovine immunoglobulins:
In order to measure mucosal permeability and possible systemic uptake of undegraded or partially degraded bovine proteins, sera from the patients were collected at various time-points before and during oral immunoglobulin therapy.
Blood samples were collected 3 h after administration of the bovine immunoglobulin product when maximum uptake of ingested protein is to be expected. The sera (collected from days Ϫ4, 3, 10, 17, 24 and 31 after BMT and referred to as sample 1, 2 etc) were kept frozen until analyzed by a sandwich ELISA where microtiter plates were coated with unconjugated sheep anti-bovine IgG diluted 1:500 (The Binding Site, Birmingham, UK), followed by incubation with dilutions of the patient serum. Purified bovine IgG (Jacksons Immuno Research Laboratories, West Grove, PA, USA) and a negative human serum sample were included as controls. Bound antibodies were detected with Results are given as CFU/ml of mouth wash.
alkaline phosphatase or peroxidase conjugated sheep-antibovine IgG diluted 1:500 (The Binding Site) and substrate (p-nitrophenyl phosphate) (Sigma Diagnostics, St Louis, MO, USA). Fecal samples were collected on days Ϫ4, 10, 17, 24 and 31 of transplant. The samples were prepared and tested for their content of undegraded immunoglobulins determined by a sandwich ELISA as described previously.
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Results
Yeast colonization in BMT recipients and colonization pattern in non-Ig-treated BMT patients
Twenty-seven of the 59 BMT patients (sampled prior to BMT) were initially free of oral yeast (colonization rate 54%). Of the 32 positive patients, only two carried Candida glabrata whereas the remaining isolates were all identified as Candida albicans.
The natural course of Candida growth in the group of 19 control patients was studied in detail and the result is given in Table 1 . In this group, 10 subjects (1-10) were initially free of oral yeast but four of these (7-10) later became colonized. In the nine patients who were initially colonized, four had a low initial number of yeasts (Ͻ100 CFU/ml). Two of these later became negative whereas the remaining two patients showed increasing numbers of colonies with time (Table 1 ). However, the five patients who showed a high number of Candida organisms in the pre-transplant sample (Ͼ100 CFU/ml of mouth wash), all continued to be colonized throughout the study period ( Figure 2 , Table 1 ).
Influence of oral administration of bovine anti-Candida antibodies on colonization
Treatment with bovine anti-Candida antibodies was carried out in two groups of BMT patients. In the first group, seven of the nine consecutively enrolled patients showed low (n ϭ 3) or undetectable (n ϭ 4) levels of Candida in the initial mouth wash. One of the former later became free of oral yeast and two of the latter remained culture negative. In the two heavily colonized patients, the initial number of CFU/ml was Ͼ100 and although the result precludes any firm conclusion, there was a decrease in the number of CFU/ml during treatment, suggestive of a therapeutic effect (data not shown). However, neither of the two patients became culture negative. As patients with a low level of initial colonization were difficult to evaluate, we subsequently treated only patients with an initial level of Ͼ100 CFU/ml in the mouth wash. Of the 31 consecutive patients evaluated for enrollment, 18 were excluded (15 were free of oral yeast and three had Ͻ100 CFU/ml). Of the remaining 13 patients, one declined taking part in the study, one could not drink the antibody solution due to severe mucositis and one was later excluded from the study as he was given systemic antifungal therapy (liposomal amphotericin B) due to suspected but not culture-proven fungal infection. The course of the 10 patients who were evaluated is given in Figure 2 . Although compliance was far better than in the first treatment series (Table 2, Figure 2 ), some patients still had difficulties in taking the full course of therapy, usually due to severe mucositis. However, even some patients receiving only a limited number of doses showed a therapeutic response (Figure 2 ). There was some fluctuation of mouth CFUs during therapy, but in seven of 10 patients a reduction of CFUs could be seen.
Adverse events
No serious adverse events were noted in the patient groups. Theoretically, systemic uptake of bovine immunoglobulins from the gut may result in immunization of the recipient with ensuing possibilities for hypersensitivity reactions. This may be of particular relevance in BMT patients who frequently suffer from severe mucositis which would allow uptake of an increased amount of undigested or partly digested bovine proteins. However, although undigested immunoglobulins could be found in the stool of some of the randomly selected patient samples, only minute amounts were found in sera from the BMT recipients. There was no difference between the groups of treated and untreated patients (Table 3) , suggesting uptake from dietary sources at least in the latter.
Discussion
Effective antifungal prophylaxis is becoming more important both in organ and bone marrow transplant patients who are frequently colonized with Candida albicans and thus highly susceptible to invasive fungal infections. Currently available topical prophylaxis is largely ineffective. However, systemic prophylaxis with fluconazole has been shown in previous studies to prevent many types of Candida infections except for those caused by Candida krusei and, as a consequence, the latter are becoming more frequent among transplant patients. 11 This form of prophylaxis has also, as expected, been associated with an increasing incidence of infections with drug resistant species such as Candida glabrata both in BMT 21 and AIDS The initial rate of colonization in BMT recipients observed in this study (47%) was slightly lower than that reported by us previously (62-76%) 7 but it is unknown whether this is due to chance or alterations in conditioning and treatment regimens. In our previous studies, as well in the present group of non-Ig-treated BMT patients, the colonization rate increased over time.
Persistent fungal colonization despite administration of orally administered nystatin in a daily dose of 30 million IU has previously been reported. 24 This is consistent with findings in our own transplant unit where we even found an increase in the proportion of patients colonized with time after BMT in spite of continuous nystatin treatment. While using bovine anti-Candida antibodies however, a reduction in colonization burden was seen during treatment in 7/10 patients with Ͼ100 CFU prior to treatment, one of whom ( Figure 2 , patient 5) became completely negative.
Oral administration of bovine immunoglobulin preparations, which contain anti-Candida antibodies, presents an option for antifungal prophylaxis. Purified immunoglobulins from immunized cows have previously been shown to protect against challenge with a variety of pathogens in man and also to attenuate or even eliminate certain infections (for review see Ref. 15) . Antibody preparations against candidiasis 16 and cryptosporidiosis [25] [26] [27] [28] [29] have also been successfully employed in immunocompromised patients.
Compliance constituted a problem in the first treatment group but improved considerably in the second treatment series when a chocolate-based drink was used as a drug vehicle. Patients all received a standardized treatment schedule of 10 g of the antibody preparation daily. As some of the patients (exemplified by patients 2, 3 and 5 in Figure  2 ) showed a poor response to treatment, it is questionable if this dose or mode of administration is sufficient for therapy. Higher doses of a product derived from colostrum of nonimmunized cows have previously been effectively employed in AIDS patients with chronic diarrhea due to Cryptosporidia 30 or of unknown etiology. 31, 32 However, the poor clinical condition of BMT recipients may reduce the possibility of exploring the benefits of dose escalation. A possible strategy for improving a future therapeutic preparation would be to increase the concentration of antibodies against crucial surface determinants on the yeast cells such as adhesion molecules and/or to deliver with excipient to increase mucosal adherence and dwelling time.
Concentration of human immunoglobulins in the intestine of normal healthy adults is in the order of 10-100 mg/l, with higher levels found in patients with gastrointestinal disorders. 33 The proportion of antibodies specific to any one pathogen would be expected to constitute a very small fraction thereof (less than 1 per 10 6 ) even in individuals who are immune to the pathogen in question. Indeed, the daily from the patients. We also want to thank Kerstin Karlsson at Division of Microbiology at Huddinge Hospital for extraction of fecal samples.
